Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 398 abstracts

no pagination
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. Journal of hematology & oncology. 2014 Sep;7:58.   PMCID: 4172963
Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer. J Gastrointest Surg. 2014 Jan;18(1):69-74.
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC. Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. J Urol. 2014 Nov;192(5):1349-54.   PMCID: PMC4422495
Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll PR, Davies BJ, Chan JM. Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE. J Urol. 2014 Apr;191(4):971-6.   PMCID: PMC5480381
Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):145-52.
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46.
Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014 Nov;147(5):1146-8.
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 06;123(6):837-42.   PMCID: PMC5527396
Boland PM, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock?. Curr Opin Oncol. 2013 Jul;25(4):417-24.   PMCID: No NIH funding
Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013 May;49(7):1521-9.   PMCID: *
Kotredes KP, Gamero AM. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res. 2013 Apr;33(4):162-70.   PMCID: Pmc3624694
Movva S. Emerging therapies for sarcoma. Curr Probl Cancer. 2013 Mar;37(2):87-101.   PMCID: Review
Obeid EI, Conzen SD. The role of adrenergic signaling in breast cancer biology. Cancer Biomark. 2013 Jan;13(3):161-9.
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr;129(1):86-91.   PMCID: PMC 3712785
Vadakara J, von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am. 2013 Oct;27(5):905-20.   PMCID: Pmc3792495
Asge Technology Committee, Kethu SR, Banerjee S, Barth BA, Desilets DJ, Kaul V, Pedrosa MC, Pfau PR, Pleskow DK, Tokar JL, Wang A, Song LM, Rodriguez SA. Endoluminal bariatric techniques. Gastrointestinal endoscopy. 2012 Jul;76(1):1-7.   PMCID: not NIH funded
Canter D, Simhan J, Smaldone MC, Lebed B, Tokar JL, Wu KN, Uzzo RG, Gustafson KS, Patchefsky AS, Plimack ER, Hoffman JP, Kutikov A. Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreas. Urology. 2012 Feb;79(2):e9-10.   PMCID: not NIH funded
Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer. 2012 Dec;43(4):562-9.   PMCID: 3400721
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use drug therapy pathology Female Antineoplastic Agents Aged Middle Aged Male methods adverse effects metabolism Protein Kinase Inhibitors Neoplasm Staging Adult Antineoplastic Combined Chemotherapy Protocols therapy Molecular Targeted Therapy Treatment Outcome pharmacology administration & dosage secondary Kaplan-Meier Estimate Prognosis analogs & derivatives Urinary Bladder Neoplasms Lung Neoplasms antagonists & inhibitors etiology Ovarian Neoplasms diagnosis Lymphatic Metastasis Transitional Cell Carcinoma Follow-Up Studies Adenocarcinoma Paclitaxel chemically induced 80 and over Aged genetics Neoplasms drug effects Disease-Free Survival Local Neoplasm Recurrence Signal Transduction Adolescent Drug Administration Schedule Retrospective Studies Non-Small-Cell Lung Carcinoma Breast Neoplasms surgery Organoplatinum Compounds Colorectal Neoplasms Peritoneal Neoplasms immunology Monoclonal Antibodies-Humanized Young Adult Folic Acid Psychological Stress health care Mutation Research Design Quality of Health Care Angiogenesis Inhibitors Ki-67 Antigen Pdgfra Acne Vulgaris Cystectomy Fatigue drug Pancreatic Ducts Vascular Endothelial Growth Factor A epidemiology Soft Tissue Neoplasms Program Development Camptothecin blood Disease Progression Area Under Curve Gastrointestinal Agents Kit hospitals Hydroxamic Acids Gastroenterology Fallopian Tube Neoplasms quality indicators mortality Botulinum Toxins Salvage Therapy Proportional Hazards Models Pancreatic Neoplasms Liver Neoplasms Tumor Biomarkers MAP Kinase Kinase 2 Metabolic Clearance Rate Prostatic Neoplasms Sarcoma Cyclin-Dependent Kinase Inhibitor p21 chemotherapy Hospitals Prospective Studies Imidazoles Gist Dermatitis Adrenergic beta-Antagonists Igf-1r Indazoles local Bevacizumab Combination Drug Therapy Practice Guidelines as Topic Lymph Nodes Hepatectomy Gastrointestinal Stromal Tumors Smooth Muscle non-squamous Fluorouracil Neoplasm Drug Resistance Rituximab United States Neoplasm DNA Neutropenia non-small-cell lung cancer bevacizumab Hsp90 Gastrointestinal Endoscopy disease progression Interferons instrumentation Neurotoxins Monoclonal Antibodies-Murine-Derived Evidence-Based Medicine Carboplatin Pyrazoles economics prostate Adrenergic Receptors-beta physiology Drug Dose-Response Relationship Neoplasm Antigens Pancreatic Cyst Obesity Central Nervous System Neoplasms Drug Costs ultrastructure Immunotherapy Patient Selection Gastrointestinal Neoplasms Large B-Cell Lymphoma-Diffuse pharmacokinetics Doxorubicin Neoplasm Invasiveness
Last updated on Friday, January 03, 2020